InvAscent

Premium

Healthcare

31 January, 2019

InvAscent's third fund strikes two more deals; hits final close

Healthcare private equity firm InvAscent has struck two new deals from its third fund that just marked its final close, ......

Premium

Healthcare

22 November, 2018

InvAscent topping up oversubscribed healthcare PE fund

Healthcare private equity firm InvAscent is set to add more money to its India-focused third fund before hitting the final ......

Premium

Healthcare

22 November, 2018

Tata Capital targets bigger corpus for second healthcare private equity fund

Tata Capital Ltd has formally kicked off a process to mobilise capital for its second healthcare private equity fund, targeting ......

Premium

Healthcare

20 September, 2018

Mid-market PE consortium in talks to buy Actis' stake in Symbiotec

Actis Advisers Pvt. Ltd is in the final stages of negotiations with a consortium of fellow private equity firms to ......

Premium

Healthcare

20 August, 2018

Evolvence India Life Sciences Fund fully exits Chennai drugmaker

Evolvence India Life Sciences Fund, the debut healthcare fund managed by private equity firm InvAscent, has fully exited its nine-year-old ......

Premium

Healthcare

19 July, 2018

India Life Sciences Fund makes new pharma bet

India Life Sciences Fund II, which is advised by InvAscent India, has struck a new deal in the pharmaceuticals sector ......

Premium

Finance

05 February, 2018

Healthcare-focussed PE firm InvAscent's third fund oversubscribed

Healthcare-focussed private equity firm InvAscent is aiming to mark the final close of its third fund next month after surpassing ......

Premium

Healthcare

19 May, 2017

India Life Sciences Fund II makes new pharma bet

Healthcare-focussed private equity fund India Life Sciences Fund II, which is advised by InvAscent India, has struck a new deal ......

Premium

Healthcare

29 November, 2016

How scalable are IVF firms for PE/VC investments amid regulatory uncertainty?

Just a couple of months after the Cabinet approved a bill to ban commercial surrogacy, two contrasting developments occurred in ......